Mosca L, Barrett-Connor E, Wenger NK (2011) Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 124(19):2145–2154

Article  PubMed  PubMed Central  Google Scholar 

Biagini E, Berardini A, Graziosi M et al (2012) Gender effect on cardiomyopathy. G Ital Cardiol (Rome) 13(6):424–431

PubMed  Google Scholar 

Pyatt JR, Dubey G (2011) Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J 87(1023):34–39

Article  PubMed  Google Scholar 

DeFilippis EM, Beale A, Martyn T et al (2022) Heart failure subtypes and cardiomyopathies in women. Circ Res 130(4):436–454

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bello NA, Arany Z (2015) Molecular mechanisms of peripartum cardiomyopathy: a vascular/hormonal hypothesis. Trends Cardiovasc Med 25(6):499–504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilfiker-Kleiner D, Haghikia A, Berliner D et al (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38(35):2671–2679

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121(13):1465–1473

Article  CAS  PubMed  Google Scholar 

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J et al (2018) 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 39(34):3165–3241

Article  PubMed  Google Scholar 

Trongtorsak A, Kittipibul V, Mahabir S et al (2022) Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis. Heart Fail Rev 27(2):533–543

Article  CAS  PubMed  Google Scholar 

Maron BJ, McKenna WJ, Danielson GK et al (2023) American college of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy a report of the american college of cardiology foundation task force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines. J Am Coll Cardiol 42(9):1687–713

Article  Google Scholar 

Kubo T, Kitaoka H, Okawa M et al (2010) Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: results from Kochi RYOMA study. J Cardiol 56(3):314–319

Article  PubMed  Google Scholar 

Olivotto I, Maron MS, Adabag AS et al (2005) Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):480–487

Article  PubMed  Google Scholar 

Wang Y, Wang J, Zou Y et al (2014) Female sex is associated with worse prognosis in patients with hypertrophic cardiomyopathy in China. PLoS ONE 9(7):e102969

Article  PubMed  PubMed Central  Google Scholar 

Geske JB, Ong KC, Siontis KC et al (2017) Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J 38(46):3434–3440

Article  PubMed  PubMed Central  Google Scholar 

Butters A, Lakdawala NK, Ingles J (2021) Sex differences in hypertrophic cardiomyopathy: interaction with genetics and environment. Curr Heart Fail Rep 18(5):264–273

Article  PubMed  PubMed Central  Google Scholar 

Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128(10):1554–1575

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falk RH, Alexander KM, Liao R et al (2016) AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68(12):1323–1341

Article  PubMed  Google Scholar 

Zampieri M, Argiro A, Allinovi M et al (2022) Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. Int J Cardiol 15(351):71–77

Article  Google Scholar 

Morfino P, Aimo A, Panichella G, Rapezzi C, Emdin M (2022) Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev 27(6):2187–2200. https://doi.org/10.1007/s10741-022-10237-7

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585–2594

Article  CAS  PubMed  Google Scholar 

Maurer MS, Hanna M, Grogan M et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161–172

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruno M, Castano A, Burton A et al (2021) Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev 26(1):35–45

Article  CAS  PubMed  Google Scholar 

Lane T, Fontana M, Martinez-Naharro A et al (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1):16–26

Article  CAS  PubMed  Google Scholar 

Damy T, Kristen AV, Suhr OB et al (2022) Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 43(5):391–400. https://doi.org/10.1093/eurheartj/ehz173

Batra J, Rosenblum H, Defilippis EM et al (2021) Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutation: insights from noninvasive pressure-volume analysis. J Card Fail 27(1):67–74

Article  PubMed  Google Scholar 

Caponetti AG, Rapezzi C, Gagliardi C et al (2021) Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. JACC Heart Fail 9(10):736–746

Article  PubMed  Google Scholar 

Rapezzi C, Riva L, Quarta CC et al (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1):40–48

Article  CAS  PubMed  Google Scholar 

Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554–1568

Article  PubMed  PubMed Central  Google Scholar 

Barrett CD, Alexander KM, Zhao H et al (2020) Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail 8(6):461–468

Article  PubMed  Google Scholar 

Trivieri MG, Spagnolo P, Birnie D et al (2020) Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol 76(16):1878–1901

Article  PubMed  PubMed Central  Google Scholar 

Rybicki BA, Major M, Popovich J Jr et al (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241

Article  CAS  PubMed  Google Scholar 

Villard E, Perret C, Gary F et al (2011) A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 32(9):1065–1076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Azaouagh A, Churzidse S, Konorza T et al (2011) Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol : official journal of the German Cardiac Society 100(5):383–394

Article  CAS  Google Scholar 

Fazio G, Corrado G, Novo G et al (2010) Ventricular dysfunction and number of non compacted segments in non compaction: non-independent predictors. Int J Cardiol 141(3):250–253

Article  PubMed  Google Scholar 

Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503–3626

Article  CAS  PubMed  Google Scholar 

Orstavik KH (2009) X chromosome inactivation in clinical practice. Hum Genet 126(3):363–373

Article  PubMed  Google Scholar 

Di Toro A, Favalli V, Arbustini E (2018) Anderson-Fabry disease. J Cardiovasc Med (Hagerstown) 19(Suppl 1):e1–e5

Article  PubMed  Google Scholar 

Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242

Article  CAS  PubMed  Google Scholar 

Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28(10):1228–1235

Article  PubMed  Google Scholar 

Elliott P, Baker R, Pasquale F et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart (British Cardiac Society) 97(23):1957–1960